EP Patent

EP2462921A1 — Liquid pharmaceutical compositions for the treatment of a posterior eye disease

Assigned to Novaliq GmbH · Expires 2012-06-13 · 14y expired

What this patent protects

The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the post…

USPTO Abstract

The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

Drugs covered by this patent

Patent Metadata

Patent number
EP2462921A1
Jurisdiction
EP
Classification
—
Expires
2012-06-13
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.